Crisis brings danger and opportunity. The COVID-19 pandemic will go down in history as an unprecedented crisis in the modern world, causing disruption and high death rates in nearly every country. The long-term impact of the pandemic is yet to be assessed. There are fears of a second wave and of deepening economic recession. Social inequality has increased, but there are also local and national initiatives providing help to those most in need. Scientists are responding to the desperate calls for effective vaccines and medications. Many research studies are underway and the knowledge that is gathered is shared and expanded internationally. As the lockdown is lifted and restrictions eased, we face the challenge of deciding whether to build on what we have learnt, or revert to our old ways.
The Journal of Dual Diagnosis mainly focuses in the field of Substance Use Disorder, co-occurring disorders, dementia, Dual Diagnosis Treatment, Clinical Diagnosis of Depression, Autism Diagnosis, Alzheimer Diagnosis, Schizophrenia Diagnosis, Psychiatric Diagnosis, and Anxiety Diagnosis. It is an area of great interest for specialists in addiction medicine, as patients with dual diagnosis pose special diagnostic and management problems. It is of increasing interest to general psychiatrists, who although recognizing both disorders, may be frustrated in their management of them, especially if trying to treat these cases without the benefit of a multidisciplinary team.
Journal accepts original manuscripts in the form of Research Articles, Review Articles, Clinical Reviews, Commentaries, Case Reports, Perspectives and Short Communications .
You can Submit manuscript directly online https://www.imedpub.com/submissions/dual-diagnosis-open-access.html or as an attachment to this E-mail: dualdiagnosis@emedsci.com
Articles will be paid high attention during the Publication any immediate submission is highly appreciable.
The journal offers author benefits which include:
Regards, Nancy Ella Journal Editor Dual Diagnosis: Open Access WhatsApp: +1-947-333-4405